Inotropes

Journal of the American College of Cardiology

Volumn 63, Issue 20, 2014, Pages 2069-2078

  Francis, Gary S ^a   Bartos, Jason A ^a   Adatya, Sirtaz ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

acute heart failure; cardiogenic shock; inotrope

Indexed keywords

DIGOXIN; DOBUTAMINE; DOPAMINE; INOTROPIC AGENT; ISTAROXIME; LEVOSIMENDAN; MILRINONE; NORADRENALIN; OMECAMTIV MECARBIL; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ARTICLE; CARDIOGENIC SHOCK; DRUG MECHANISM; GENE; GENE THERAPY; GENE TRANSFER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART HEMODYNAMICS; HEART RATE; HOME CARE; HUMAN; MORTALITY; PRIORITY JOURNAL; SEPTIC SHOCK; SERCA2A GENE; SURVIVAL; SYSTOLIC HEART FAILURE; VASOCONSTRICTION; VASODILATATION;

ACUTE HEART FAILURE; CARDIOGENIC SHOCK; INOTROPE;

CARDIOTONIC AGENTS; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; SHOCK, CARDIOGENIC; SYSTOLE; TREATMENT OUTCOME;

EID: 84901020819     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.01.016     Document Type: Review

References (77)

1. J. Lindenfeld, N.M. Albert, J.P. Boehmer Heart Failure Society of America HFSA 2010 comprehensive heart failure practice guideline J Card Fail 16 2010 e1 e194
2. U. Elkayam, G. Tasissa, and C. Binanay et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure Am Heart J 153 2007 98 104
3. G.M. Felker, R.L. Benza, and A.B. Chandler et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study J Am Coll Cardiol 41 2003 997 1003
4. M. Bayram, L. De Luca, M.B. Massie, and M. Gheorghiade Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes Am J Cardiol 96 2005 47G 58G
5. M.S. Cuffe, R.M. Califf, and K.F. Adams Jr. et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial JAMA 287 2002 1541 1547
6. F. Follath, J.G. Cleland, and H. Just et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial Lancet 360 2002 196 202
7. A. Mebazaa, M.S. Nieminen, and M. Packer et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial JAMA 297 2007 1883 1891
8. W.T. Abraham, K.F. Adams, and G.C. Fonarow et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Am Coll Cardiol 46 2005 57 64
9. J.J. Teuteberg, G.C. Stewart, and M. Jessup et al. Implant strategies change over time and impact outcomes: insights from the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) J Am Coll Cardiol 1 2013 369 378
10. M. Gheorghiade, J. St Clair, C. St Clair, and G.A. Beller Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators J Am Coll Cardiol 9 1987 849 857
11. H. Krum, J.T. Bigger Jr., R.L. Goldsmith, and M. Packer Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure J Am Coll Cardiol 25 1995 289 294
12. M. Gheorghiade, D.J. van Veldhuisen, and W.S. Colucci Contemporary use of digoxin in the management of cardiovascular disorders Circulation 113 2006 2556 2564
13. M. Gheorghiade, and D. Ferguson Digoxin. A neurohormonal modulator in heart failure? Circulation 84 1991 2181 2186
14. R. Jaeschke, A.D. Oxman, and G.H. Guyatt To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis Am J Med 88 1990 279 286
15. M. Packer, M. Gheorghiade, and J.B. Young et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting- enzyme inhibitors. RADIANCE study N Engl J Med 329 1993 1 7
16. B.F. Uretsky, J.B. Young, F.E. Shahidi, L.G. Yellen, M.C. Harrison, and M.K. Jolly Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group J Am Coll Cardiol 22 1993 955 962
17. M. Gheorghiade, and E. Braunwald Reconsidering the role for digoxin in the management of acute heart failure syndromes JAMA 302 2009 2146 2147
18. P.J. Hauptman, and R.A. Kelly Digitalis Circulation 99 1999 1265 1270
19. S. Naqvi, I. Ahmed, R. Siddiqi, and S.A. Hussain Digoxin as a rescue drug in intra aortic balloon pump and inotrope dependent patients J Ayub Med Coll Abbottabad 22 2010 8 12
20. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group N Engl J Med 336 1997 525 533
21. G.S. Francis The contemporary use of digoxin for the treatment of heart failure Circ Heart Fail 1 2008 208 209
22. I.C. Van Gelder, H.F. Groenveld, and H.J. Crijns et al. Lenient versus strict rate control in patients with atrial fibrillation N Engl J Med 362 2010 1363 1373
23. S.S. Rathore, J.P. Curtis, Y. Wang, M.R. Bristow, and H.M. Krumholz Association of serum digoxin concentration and outcomes in patients with heart failure JAMA 289 2003 871 878
24. S.A. Hunt, W.T. Abraham, and M.H. Chin et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 2009 e1 e90
25. J.J. McMurray, S. Adamopoulos, and S.D. Anker et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 2012 1787 1847
26. S.S. Rathore, Y. Wang, and H.M. Krumholz Sex-based differences in the effect of digoxin for the treatment of heart failure N Engl J Med 347 2002 1403 1411
27. K.F. Adams Jr., J.H. Patterson, and W.A. Gattis et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis J Am Coll Cardiol 46 2005 497 504
28. L.I. Goldberg Cardiovascular and renal actions of dopamine: potential clinical applications Pharmacol Rev 24 1972 1 29
29. R. Bellomo, M. Chapman, S. Finfer, K. Hickling, and J. Myburgh Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group Lancet 356 2000 2139 2143
30. H.H. Chen, K.J. Anstrom, and M.M. Givertz et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial JAMA 310 2013 2533 2543
31. E.H. Sonnenblick, W.H. Frishman, and T.H. LeJemtel Dobutamine: a new synthetic cardioactive sympathetic amine N Engl J Med 300 1979 17 22
32. C.V. Leier, and D.V. Unverferth Drugs five years later. Dobutamine Ann Intern Med 99 1983 490 496
33. G.S. Francis, B. Sharma, and M. Hodges Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse Am Heart J 103 1982 995 1000
34. G.S. Spear Eosinophilic explant carditis with eosinophilia: hypersensitivity to dobutamine infusion J Heart Lung Transplant 14 1995 755 760
35. O.M. El-Sayed, R.R. Abdelfattah, R. Barcelona, and C.V. Leier Dobutamine-induced eosinophilia Am J Cardiol 93 2004 1078 1079
36. S.A. Chapman, T. Stephan, K.D. Lake, S.W. Sonnesyn, and R.W. Emery Fever induced by dobutamine infusion Am J Cardiol 74 1994 517
37. N. Akhtar, E. Mikulic, J.N. Cohn, and M.H. Chaudhry Hemodynamic effect of dobutamine in patients with severe heart failure Am J Cardiol 36 1975 202 205
38. D.A. Unverferth, M. Blanford, R.E. Kates, and C.V. Leier Tolerance to dobutamine after a 72 hour continuous infusion Am J Med 69 1980 262 266
39. C.V. Leier, J. Webel, and C.A. Bush The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure Circulation 56 1977 468 472
40. D.M. Mancini, M. Schwartz, N. Ferraro, R. Seestedt, B. Chance, and J.R. Wilson Effect of dobutamine on skeletal muscle metabolism in patients with congestive heart failure Am J Cardiol 65 1990 1121 1126
41. D.V. Unverferth, R.D. Magorien, R.P. Lewis, and C.V. Leier Long-term benefit of dobutamine in patients with congestive cardiomyopathy Am Heart J 100 1980 622 630
42. C.S. Liang, L.G. Sherman, J.U. Doherty, K. Wellington, V.W. Lee, and W.B. Hood Jr. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine Circulation 69 1984 113 119
43. M.B. Patel, I.V. Kaplan, and R.N. Patni et al. Sustained improvement in flow-mediated vasodilation after short-term administration of dobutamine in patients with severe congestive heart failure Circulation 99 1999 60 64
44. J.A. Collins, M.A. Skidmore, D.B. Melvin, and P.J. Engel Home intravenous dobutamine therapy in patients awaiting heart transplantation J Heart Transplant 9 1990 205 208
45. L.W. Miller, E.J. Merkle, and S.H. Jennison Outpatient use of dobutamine to support patients awaiting heart transplantation J Heart Lung Transplant 13 1994 S126 S129
46. A.P. Sindone, A.M. Keogh, P.S. Macdonald, C.J. McCosker, and A.F. Kaan Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy Am Heart J 134 1997 889 900
47. C.M. O'Connor, W.A. Gattis, and B.F. Uretsky et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST) Am Heart J 138 1999 78 86
48. D. De Backer, P. Biston, and J. Devriendt et al. Comparison of dopamine and norepinephrine in the treatment of shock N Engl J Med 362 2010 779 789
49. S. Jolly, G. Newton, and E. Horlick et al. Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction Am J Cardiol 96 2005 1617 1620
50. J.S. Hochman Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm Circulation 107 2003 2998 3002
51. C.B. Overgaard, and V. Dzavik Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease Circulation 118 2008 1047 1056
52. M.A. Konstam, and R.J. Cody Short-term use of intravenous milrinone for heart failure Am J Cardiol 75 1995 822 826
53. J.L. Anderson, D.S. Baim, S.A. Fein, R.A. Goldstein, T.H. LeJemtel, and M.J. Likoff Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study J Am Coll Cardiol 9 1987 711 722
54. R. Grose, J. Strain, M. Greenberg, and T.H. LeJemtel Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure J Am Coll Cardiol 7 1986 1107 1113
55. M. Packer, J.R. Carver, and R.J. Rodeheffer et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group N Engl J Med 325 1991 1468 1475
56. M.M. Givertz, C. Andreou, C.H. Conrad, and W.S. Colucci Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships Circulation 115 2007 1218 1224
57. K. Todaka, J. Wang, and G.H. Yi et al. Effects of levosimendan on myocardial contractility and oxygen consumption J Pharmacol Exp Ther 279 1996 120 127
58. L. De Luca, W.S. Colucci, M.S. Nieminen, B.M. Massie, and M. Gheorghiade Evidence-based use of levosimendan in different clinical settings Eur Heart J 27 2006 1908 1920
59. M. Gheorghiade, J.R. Teerlink, and A. Mebazaa Pharmacology of new agents for acute heart failure syndromes Am J Cardiol 96 2005 68G 73G
60. M.T. Slawsky, W.S. Colucci, and S.S. Gottlieb et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators Circulation 102 2000 2222 2227
61. Packer M. REVIVE II: multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. 2005. American Heart Association Scientific Sessions; Dallas, TX; November 14, 2005.
62. M.S. Nieminen, J.G. Cleland, and J. Eha et al. Oral levosimendan in patients with severe chronic heart failure - the PERSIST study European journal of heart failure 10 2008 1246 1254
63. M. Bayeva, M. Gheorghiade, and H. Ardehali Mitochondria as a therapeutic target in heart failure J Am Coll Cardiol 61 2013 599 610
64. F.I. Malik, J.J. Hartman, and K.A. Elias et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure Science 331 2011 1439 1443
65. D.A. Kass, and R.J. Solaro Mechanisms and use of calcium-sensitizing agents in the failing heart Circulation 113 2006 305 315
66. J.R. Teerlink, C.P. Clarke, and K.G. Saikali et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study Lancet 378 2011 667 675
67. Y.T. Shen, F.I. Malik, and X. Zhao et al. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure Circ Heart Fail 3 2010 522 527
68. L.A. Leinwand, and R.L. Moss Medicine. Chemically tuned myosin motors Science 331 2011 1392 1393
69. J.G. Cleland, J.R. Teerlink, and R. Senior et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial Lancet 378 2011 676 683
70. M. Jessup, B. Greenberg, and D. Mancini et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure Circulation 124 2011 304 313
71. S.E. Lehnart, L.S. Maier, and G. Hasenfuss Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart Heart Fail Rev 14 2009 213 224
72. M.J. Byrne, J.M. Power, A. Preovolos, J.A. Mariani, R.J. Hajjar, and D.M. Kaye Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals Gene Ther 15 2008 1550 1557
73. R.J. Hajjar, K. Zsebo, and L. Deckelbaum et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure J Card Fail 14 2008 355 367
74. B.E. Jaski, M.L. Jessup, and D.M. Mancini et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial J Card Fail 15 2009 171 181
75. M. Gheorghiade, J.E. Blair, and G.S. Filippatos et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure J Am Coll Cardiol 51 2008 2276 2285
76. H.N. Sabbah, M. Imai, D. Cowart, A. Amato, P. Carminati, and M. Gheorghiade Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure Am J Cardiol 99 2007 41A 46A
77. L.A. Allen, L.W. Stevenson, and K.L. Grady et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association Circulation 125 2012 1928 1952